Life Technologies Corp. v. Promega Corp.

{{Infobox SCOTUS case

|Litigants=Life Technologies Corp. v. Promega Corp.

|ArgueDate=December 6

|ArgueYear=2016

|DecideDate=February 22

|DecideYear=2017

|FullName=Life Technologies Corporation, et al., Petitioners v. Promega Corporation

|USVol=580

|USPage=140

|ParallelCitations=137 S. Ct. 734; 197 L. Ed. 2d 33; 121 U.S.P.Q.2d 1641

|Docket=14–1538

|OpinionAnnouncement=

|OralArgument=

|Prior=Promega Corp. v. Life Techs. Corp., 773 F.3d [https://www.leagle.com/decision/infco20141215154 1338] (Fed. Cir. 2014); cert. granted, 136 S. Ct. 2505 (2016).

|Procedural=On writ of certiorari to the United States Court of Appeals for the Federal Circuit

|Subsequent=

|Holding= The sale of a single component of a patented invention in a foreign market does not give rise to liability under the Patent Act of 1952.

|Majority=Sotomayor

|JoinMajority=Kennedy, Ginsburg, Breyer, Kagan; Thomas, Alito (all but Part II–C)

|Concurrence=Alito (in part)

|JoinConcurrence=Thomas

|NotParticipating=Roberts

|LawsApplied=Patent Act of 1952, {{USC|35|271}} et seq.

}}

Life Technologies Corp. v. Promega Corp., 580 U.S. ___ (2017), was a case in which the United States Supreme Court clarified the application of the Patent Act of 1952 to the sale of components of patented inventions in foreign markets.{{ussc|name=Life Technologies Corp. v. Promega Corp.|volume=580|year=2017|docket=14-1538}}, slip. op. at 1. In an opinion written by Associate Justice Sonia Sotomayor, the Court held that the sale of a "single component" in a foreign market "does not constitute a substantial portion of the components that can give rise to liability under [the Patent Act of 1952]."Life Technologies Corp., slip op. at 1, 11 (citing {{USCSub|35|271|f|1}}). Justice Samuel Alito wrote an opinion concurring in part and concurring in the judgment, in which he was joined Justice Clarence Thomas.Life Technologies Corp., slip op. at 1 (Alito, J., concurring in part and concurring in the judgment). Chief Justice John Roberts took no part in the decision of the case.Life Technologies Corp., slip op. at 11.